Q4 24 EPS
$-1.27
BEAT +3.52%
Est. $-1.32
Q4 24 Revenue
$12.9M
BEAT +58.94%
Est. $8.1M
vs S&P Since Q4 24
+25.3%
BEATING MARKET
NTLA +50.0% vs S&P +24.7%
Full Year 2024 Results
FY 24 EPS
$-5.25
FY 24 Revenue
$57.9M
Market Reaction
Did NTLA Beat Earnings? Q4 2024 Results
Intellia Therapeutics posted a stronger-than-expected fourth quarter, with its per-share loss of $1.27 coming in narrower than the consensus estimate of $1.32, a beat of 3.52%, while revenue of $12.87 million cleared Wall Street expectations of $8.10… Read more Intellia Therapeutics posted a stronger-than-expected fourth quarter, with its per-share loss of $1.27 coming in narrower than the consensus estimate of $1.32, a beat of 3.52%, while revenue of $12.87 million cleared Wall Street expectations of $8.10 million by nearly 59% and surged 771.6% year over year. The primary driver behind that dramatic revenue swing was a significant recovery in collaboration revenue tied to the Regeneron agreements, which flipped from negative $1.92 million in Q4 2023 to $12.87 million this quarter. The results arrived alongside a January 2025 strategic restructuring in which the company elected to concentrate resources on its two late-stage programs, nexiguran ziclumeran for ATTR amyloidosis and NTLA-2002 for hereditary angioedema, while cutting roughly 27% of its workforce. Looking ahead, enrollment in the Phase 3 MAGNITUDE trial is on track to exceed 550 patients by year-end, and the company's $862 million cash position is expected to fund operations into the first half of 2027.
Key Takeaways
- • Increased collaboration revenue from Regeneron agreements drove $14.8 million revenue improvement year-over-year in Q4
- • Advancement of lead clinical programs drove higher R&D spending
- • Interest income of $10.6 million contributed to reducing net loss
NTLA YoY Financials
Q4 2024 vs Q4 2023, source: SEC Filings
NTLA Revenue by Segment
With YoY comparisons, source: SEC Filings
“We are off to an excellent start in 2025 with renewed focus and strong operational execution across our three, pivotal Phase 3 studies. We are excited by the clinical data presented during the fourth quarter. Our Phase 1/2 results in HAE suggest that NTLA-2002 could represent a functional cure for patients with HAE – for the first time a patient has the potential to be both free from attacks and free from chronic therapy. Similarly, the rapid, deep and durable reductions in serum TTR demonstrated to date in our Phase 1 study of nex-z in ATTR represent a highly differentiated profile that may offer patients an opportunity to stabilize or improve their clinical readouts in an otherwise unrelenting, progressive disease.”
— John Leonard, Q4 2024 Earnings Press Release
NTLA Earnings Trends
NTLA vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
NTLA EPS Trend
Earnings per share: estimate vs actual
NTLA Revenue Trend
Quarterly revenue: estimate vs actual
NTLA Quarterly Results
7 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q2 26 BEAT | $-0.90 | $-0.81 | +9.81% | $15.0M | +8.99% |
| Q1 26 BEAT | $-0.90 | $-0.81 | +9.81% | $15.0M | +8.99% |
| Q4 25 BEAT FY | $-0.96 | $-0.83 | +13.71% | $23.0M | +89.08% |
| FY Full Year | $-4.00 | $-3.81 | +4.75% | $67.7M | +18.53% |
| Q3 25 BEAT | $-0.98 | $-0.92 | +6.49% | $13.8M | -2.41% |
| Q2 25 BEAT | $-1.01 | $-0.98 | +2.51% | $14.2M | +17.12% |
| Q1 25 BEAT | $-1.27 | $-1.10 | +13.46% | $16.6M | +38.72% |
| Q4 24 BEAT FY | $-1.32 | $-1.27 | +3.52% | $12.9M | +58.94% |
| FY Full Year | — | $-5.25 | — | $57.9M | — |